Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure
暂无分享,去创建一个
[1] A. Eggermont,et al. One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases , 2004, Annals of surgery.
[2] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Eggermont,et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.
[4] H. Polk,et al. Post-Perfusion Recurrent Melanoma , 1999, Annals of Surgical Oncology.
[5] A. Eggermont,et al. Absence of Severe Systemic Toxicity After Leakage-Controlled Isolated Limb Perfusion With Tumor Necrosis Factor-α and Melphalan , 1999, Annals of Surgical Oncology.
[6] A. Eggermont,et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.
[7] S. Libutti,et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics , 1997, Cancer.
[8] P. Kam,et al. Frequency and duration of remission after isolated limb perfusion for melanoma. , 1997, Archives of surgery.
[9] P. Schlag,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.
[10] A. Eggermont,et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. , 1996, Journal of the American College of Surgeons.
[11] P. Schlag,et al. Treatment of melanoma in-transit metastases confined to the limb , 1996, Acta Chirurgica Austriaca.
[12] A. Eggermont,et al. Rationale for using TNFα and chemotherapy in regional therapy of melanoma , 1994 .
[13] A. Eggermont,et al. Systemic leakage during isolated limb perfusion for melanoma , 1993, The British journal of surgery.
[14] E. V. van Slooten,et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.
[15] A. Eggermont,et al. Fifty Tumor Necrosis Factor–Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors , 2003, Annals of surgical oncology.
[16] A. Eggermont,et al. Systemic Toxicity and Cytokine/Acute Phase Protein Levels in Patients After Isolated Limb Perfusion With Tumor Necrosis Factor-a Complicated by High Leakage , 2000, Annals of Surgical Oncology.
[17] A. Feldman,et al. Management of Extremity Recurrences After Complete Responses to Isolated Limb Perfusion in Patients With Melanoma , 1999, Annals of Surgical Oncology.
[18] C. Wiltschke,et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] N. Renard,et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[21] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .